Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary ...

Peripheral T-cell lymphomas are a rare and heterogeneous type of lymphoma, with geographical and ethnic variations in histological subtypes that differ across the world.1 In The Lancet Haematology, ...

A study on the long-term safety of CAR T-cell therapy for B-cell lymphoma patients reveals a favourable safety profile with ...

The Leukemia & Lymphoma Society (LLS) has launched a new docuseries to inform blood cancer patients, caregivers, healthcare ...

The “off-the-shelf” CAR T-cell therapy CTD402 will be evaluated in a phase 1b/2 trial for patients with T-cell acute ...

Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for ...

Researchers Uncover Mechanism That Fuels Growth of Aggressive B-Cell Lymphoma June 18 ... Details About Rare Second Cancers Related to CAR-T Therapy June 12, 2024 — A new detailed analysis ...

The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.

Corvus Pharmaceuticals' Soquelitinib shows promise for PTCL & more, but financial risks and competition raise concerns. Learn more about CRVS stock here.

The United States Cutaneous Lymphoma Consortium is a multidisciplinary society of physicians which use collaborative research and education to improve the quality of life and prognosis of patients ...